Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases

Sujata Maurya; Rashi Srivastava; Saniya Arfin; Susan Hawthorne; Niraj Kumar Jha; Kirti Agrawal; Sibi Raj; Brijesh Rathi; Arun Kumar; Riya Raj; Sharad Agrawal; Ana Cláudia Paiva-Santos; Asrar Ahmad Malik; Kamal Dua; Rakesh Rana; Shreesh Ojha; Saurabh Kumar Jha; Ankur Sharma; Dhruv Kumar; Sally A El-Zahaby; Amka Nagar

doi:10.2217/nnm-2021-0437

Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases

Sujata Maurya
, Rashi Srivastava
, Saniya Arfin
, Susan Hawthorne
, Niraj Kumar Jha
, Kirti Agrawal
, Sibi Raj
, Brijesh Rathi
, Arun Kumar
, Riya Raj
, Sharad Agrawal
, Ana Cláudia Paiva-Santos
, Asrar Ahmad Malik
, Kamal Dua
, Rakesh Rana
, Shreesh Ojha
, Saurabh Kumar Jha
, Ankur Sharma
, Dhruv Kumar
, Sally A El-Zahaby

Amka Nagar

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

87 Downloads (Pure)

Abstract

Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.

Original language	English
Pages (from-to)	2245-2264
Number of pages	20
Journal	NANOMEDICINE
Volume	17
Issue number	30
Early online date	28 Mar 2023
DOIs	https://doi.org/10.2217/nnm-2021-0437
Publication status	Published (in print/issue) - 28 Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.

Funding

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Review
biopharmacokinetic
cystic fibrosis
lung diseases
nanocarriers
nanomedicines
therapeutics

Access to Document

10.2217/nnm-2021-0437

Accepted Author ManuscriptAuthor Accepted Manuscript, 0.99 MB

Cite this

Maurya, S., Srivastava, R., Arfin, S., Hawthorne, S., Jha, N. K., Agrawal, K., Raj, S., Rathi, B., Kumar, A., Raj, R., Agrawal, S., Paiva-Santos, A. C., Malik, A. A., Dua, K., Rana, R., Ojha, S., Jha, S. K., Sharma, A., Kumar, D., ... Nagar, A. (2023). Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases. NANOMEDICINE, 17(30), 2245-2264. https://doi.org/10.2217/nnm-2021-0437

@article{030d90e699c34f4a8438ce551fef8331,

title = "Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases",

abstract = "Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.",

keywords = "Review, biopharmacokinetic, cystic fibrosis, lung diseases, nanocarriers, nanomedicines, therapeutics",

author = "Sujata Maurya and Rashi Srivastava and Saniya Arfin and Susan Hawthorne and Jha, \{Niraj Kumar\} and Kirti Agrawal and Sibi Raj and Brijesh Rathi and Arun Kumar and Riya Raj and Sharad Agrawal and Paiva-Santos, \{Ana Cl{\'a}udia\} and Malik, \{Asrar Ahmad\} and Kamal Dua and Rakesh Rana and Shreesh Ojha and Jha, \{Saurabh Kumar\} and Ankur Sharma and Dhruv Kumar and El-Zahaby, \{Sally A\} and Amka Nagar",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = mar,

day = "28",

doi = "10.2217/nnm-2021-0437",

language = "English",

volume = "17",

pages = "2245--2264",

journal = "NANOMEDICINE",

issn = "1743-5889",

publisher = "Taylor \& Francis",

number = "30",

}

Maurya, S, Srivastava, R, Arfin, S, Hawthorne, S, Jha, NK, Agrawal, K, Raj, S, Rathi, B, Kumar, A, Raj, R, Agrawal, S, Paiva-Santos, AC, Malik, AA, Dua, K, Rana, R, Ojha, S, Jha, SK, Sharma, A, Kumar, D, El-Zahaby, SA & Nagar, A 2023, 'Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases', NANOMEDICINE, vol. 17, no. 30, pp. 2245-2264. https://doi.org/10.2217/nnm-2021-0437

TY - JOUR

T1 - Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases

AU - Maurya, Sujata

AU - Srivastava, Rashi

AU - Arfin, Saniya

AU - Hawthorne, Susan

AU - Jha, Niraj Kumar

AU - Agrawal, Kirti

AU - Raj, Sibi

AU - Rathi, Brijesh

AU - Kumar, Arun

AU - Raj, Riya

AU - Agrawal, Sharad

AU - Paiva-Santos, Ana Cláudia

AU - Malik, Asrar Ahmad

AU - Dua, Kamal

AU - Rana, Rakesh

AU - Ojha, Shreesh

AU - Jha, Saurabh Kumar

AU - Sharma, Ankur

AU - Kumar, Dhruv

AU - El-Zahaby, Sally A

AU - Nagar, Amka

PY - 2023/3/28

Y1 - 2023/3/28

N2 - Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.

AB - Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.

KW - Review

KW - biopharmacokinetic

KW - cystic fibrosis

KW - lung diseases

KW - nanocarriers

KW - nanomedicines

KW - therapeutics

UR - https://www.scopus.com/pages/publications/85151168477

U2 - 10.2217/nnm-2021-0437

DO - 10.2217/nnm-2021-0437

M3 - Review article

C2 - 36975758

SN - 1743-5889

VL - 17

SP - 2245

EP - 2264

JO - NANOMEDICINE

JF - NANOMEDICINE

IS - 30

ER -

Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this